title: Chemoprevention of familial adenomatous polyposis.
abstract: Familial adenomatous polyposis (FAP) has always been first and foremost a surgical disease, whose treatment with colectomy has long been known to reduce risk of premature cancer death. The notion of reducing polyp burden and potentially delaying surgical intervention has spawned a host of "chemoprevention" trials. In this paper I selectively review the findings from these studies, highlighting trial design issues and in particular some of the limitations of historical and existing trial endpoint measures. Nonsteroidal anti-inflammatory agents have been the most commonly employed chemopreventive agents. Sulindac, largely by historical accident, has been the most extensively studied, and is widely considered the standard of care when a clinical decision to intervene medically is made. Newer trials are evaluating combinations of agents in order to take advantage of differing mechanisms of action, in the hope of achieving synergy, as no single agent predictably or completely suppresses adenoma growth. Some of these studies and other single-agent interventions are discussed, though an exploration of the various mechanisms of action is beyond the scope of this paper. It is essential that future trials focus on the issue of "clinical benefit", not simply because the US Food and Drug Administration has insisted on it, but because only real evidence-based advances can improve the standard of medical care for FAP patients. Hence my focus on issues of trial design and clinically relevant endpoints.
authors.affiliation: Department of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center, 1515 Holcombe Blvd. - Unit 1466, Houston, TX, 77030, USA. plynch@mdanderson.org.
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Lynch
mesh_terms: D011125:Adenomatous Polyposis Coli / Q000517:prevention & control* / Q000601:surgery; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000068579:Celecoxib / Q000494:pharmacology / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000639:trends; D002986:Clinical Trials as Topic; D003082:Colectomy / Q000009:adverse effects / Q000379:methods; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D000518:Eflornithine / Q000494:pharmacology / Q000627:therapeutic use; D019317:Evidence-Based Medicine / Q000379:methods*; D006801:Humans; D065286:Prophylactic Surgical Procedures / Q000009:adverse effects / Q000379:methods; D012074:Remission Induction / Q000379:methods; D013467:Sulindac / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D052246:Cyclooxygenase 2 Inhibitors; D013467:Sulindac; D000068579:Celecoxib; D001241:Aspirin; D000518:Eflornithine
keywords: Chemoprevention; Familial adenomatous polyposis (FAP); Nonsteroidal anti-inflammatory agents (NSAIDs)